Clinical trials

Healthy male and female subjects aged from 18 to 45 years; [+4]

Medical history (current or past) that in the investigator's judgment may interf... [+11]

Volunteer to participate in clinical research; Fully understand and know the stu... [+3]

Female subjects who are breastfeeding or have positive pregnancy results; [+5]

Subjects with advanced solid tumors; [+7]

Subjects who have received other antitumor therapy within the prescribed time pr... [+12]

Patients who voluntarily participate in this study, completely understand this s... [+6]

Inflammatory breast cancer. [+14]

Subjects aged between 18 and 80 years at screening; [+1]

Subjects have received or plan to receive endovascular treatment and/or intraven... [+22]

ECOG performance status of 0 to 1. [+5]

Subjects who have received the prescribed treatment at the prescribed time prior... [+16]

NMOSD as defined by either of the following 2015 criteria with anti-AQP4 antibod... [+3]

Any previous treatment with anti-CD20, eculizumab, anti-BLyS monoclonal antibody... [+15]

Subjects with advanced melanoma; [+7]

Subjects who have received other antitumor therapy within the prescribed time pr... [+12]

Subjects voluntarily participate in this study and sign informed consent. [+6]

Taking anti-tumor traditional Chinese medicines at the time of signing the ICF. [+11]

Patients who voluntarily participate in this study, completely understand this s... [+6]

Inflammatory breast cancer. [+15]

Histologically or cytologically confirmed advanced solid tumors； [+7]

Subjects who have received the prescribed other anti-tumor treatments at the pre... [+21]

Metastatic and/or unresectable advanced colorectal adenocarcinoma, or locally ad... [+7]

Subjects who have previously received anti-HER2 molecular targeted therapy; [+2]

Patients who voluntarily participate in the study, completely understand the stu... [+8]

Prior treatment with any CDK4/6 （Cyclin dependent kinase）inhibitor. [+17]